Comparative Pharmacology
Head-to-head clinical analysis: TORECAN versus TRANSDERM SCOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TORECAN versus TRANSDERM SCOP.
TORECAN vs TRANSDERM SCOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
Competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the vestibular system, gastrointestinal tract, and central nervous system, inhibiting vagal nerve activity and preventing motion-induced nausea and vomiting.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
One transdermal patch (1 mg/72 hours) applied to the hairless area behind the ear at least 4 hours before anticipated exposure; replace every 72 hours as needed.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
The terminal elimination half-life of scopolamine is approximately 9.5 hours (range 6-12 hours) following transdermal administration. In elderly patients, half-life may be prolonged to up to 20 hours.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Scopolamine is extensively metabolized; about 50% of a dose is excreted renally as metabolites and unchanged drug, with less than 10% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 30-40% of the dose.
Category C
Category C
Antiemetic
Antiemetic